Repositioning Candidate Details
| Candidate ID: | R0756 |
| Source ID: | DB05262 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Oxypurinol |
| Synonyms: | 1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione; Alloxanthine; DHPP; Oxipurinol; Oxoallopurinol; Oxypurinol |
| Molecular Formula: | C5H4N4O2 |
| SMILES: | O=C1NC2=C(C=NN2)C(=O)N1 |
| Structure: |
|
| DrugBank Description: | Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol. |
| CAS Number: | 2465-59-0 |
| Molecular Weight: | 152.1109 |
| DrugBank Indication: | Intended for the treatment of congestive heart failure and hyperuricemia. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Oxypurinol inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xanthine oxidase through negative feedback results in a decrease in the concentrations of uric acid in the blood and urine. Oxypurinol also facilitates the incorporation of hypoxanthine and xanthine into DNA and RNA, resulting in further reductions of serum uric acid concentrations. |
| Targets: | Xanthine dehydrogenase/oxidase |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |